Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.

PURPOSE We measured concentrations of human glandular kallikrein 2 (hK2), total prostate specific antigen (tPSA), free PSA (fPSA) and percent fPSA to evaluate their relationship to total prostate gland volume, benign prostatic hyperplasia (BPH) volume, total prostate cancer (PCa) volume (CaVol) and the volume of Gleason grades 4/5 cancer (CaVolGl4) in the serum of 256 patients with PCa undergoing radical retropubic prostatectomy and 185 with negative systematic sextant biopsies. MATERIALS AND METHODS Free and total PSA was measured using the Delfia Prostatus (Perkin-Elmer, Turku, Finland) total/free PSA assay and hK2 was measured using a research immunofluorometric assay. Transrectal ultrasound was used to determine total prostate and BPH volume. Total CaVol and CaVolGl4/5 were calculated using a volumetric program in specimens from 158 men with pT2a/b and 98 with pT3a or greater PCa. The Pearson correlation was performed after logarithmic conversion of PSA and hK2 levels. Benign gland, and pT2a/b and pT3a or greater PCa cases were subdivided into small vs large prostate gland volumes (42 cc or less vs greater than 42 cc). RESULTS Total prostate and BPH volumes correlated closely with free PSA (r = 0.64 to 0.65, p <0.0001) in 143 patients with negative biopsy and a prostate of greater than 42 cc. Correlations of hK2 and tPSA with total prostate and BPH volumes were weaker (r = 0.35 to 0.36 and 0.45 to 0.46, respectively). In pT2a/b and pT3a or greater PCa cases hK2 most closely correlated with CaVol (range 0.31 to 0.62, p = 0.0072 and <0.0001) and with CaVolGl4/5 (range 0.26 to 0.56, p = 0.021 and <0.0001, respectively). The tPSA level correlated significantly with CaVol and CaVolGl4/5 except in glands 42 cc or greater harboring pT2a/b PCa (p = 0.08). Free PSA correlated significantly with CaVolGl4/5 only in pT3a or greater PCa (p <0.05), and with CaVol in pT3a or greater PCa and in small prostates harboring pT2a/b PCa. CONCLUSIONS Large benign prostate gland volume affects fPSA more than tPSA in serum. In PCa hK2 more closely correlates with total cancer volume and high grade PCa volume compared with tPSA or fPSA.

[1]  A. Haese*,et al.  Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ‐confined from locally‐advanced prostate cancer in total PSA‐levels below 10 ng/ml , 2001, The Prostate.

[2]  A. Haese*,et al.  Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. , 2000, The Journal of urology.

[3]  D. Tindall,et al.  Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. , 1992, Biochemistry.

[4]  A. Rademaker,et al.  Re: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. , 1990, The Journal of urology.

[5]  S. Gautam,et al.  Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen. , 2001, The Journal of urology.

[6]  D. Tindall,et al.  Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. , 1999, Urology.

[7]  G G Klee,et al.  Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. , 1997, Urology.

[8]  T. Stamey,et al.  Biological determinants of cancer progression in men with prostate cancer. , 1999, JAMA.

[9]  J. Hugosson,et al.  Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. , 2000, Urology.

[10]  B. Morris,et al.  Primary structure of a human glandular kallikrein gene. , 1987, DNA.

[11]  H. Lilja,et al.  Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. , 1997, Biochemical and biophysical research communications.

[12]  D. Tindall,et al.  Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. , 1999, Urology.

[13]  D. Chan,et al.  Standardization of two immunoassays for human glandular kallikrein 2. , 2003, Clinical chemistry.

[14]  J. Oesterling,et al.  Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.

[15]  G. Yousef,et al.  The new human tissue kallikrein gene family: structure, function, and association to disease. , 2001, Endocrine reviews.

[16]  J. Richie,et al.  Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. , 1999, The Journal of urology.

[17]  A S Whittemore,et al.  Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer , 1993, Cancer.

[18]  T. Stamey,et al.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. , 1989, The Journal of urology.

[19]  H. Lilja,et al.  Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections. , 2000, Urology.

[20]  T. Stamey,et al.  Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients. , 1996, The Journal of urology.

[21]  A. Renshaw,et al.  Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.